Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FirSTAR Trial: CapeOX plus nivolumab for early-relapse gastric cancer after adjuvant S-1-based therapy
jRCTs031220572Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and nivolumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate. Started Mar 2023; status: active, not recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031220572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220572.